News

vVardis, the recently launched personal oral care brand by Dres Abivardi, has acquired credentis, a company founded in 2010 to develop and commercialise self-assembling peptide (SAP) technologies patented by the University of Leeds.

The credentis and vVardis’ partnership has developed a unique vVardis oral care product line, and now credentis will become the research and development department (R&D) within vVardis.

Following the acquisition, both the professional dental CURODONT™ line and the oral care vVardis products – with the proprietary CUROLOX^® & WX Technology – will form one oral care powerhouse.

Within the newly formed partnership, the credentis leadership team will continue to run credentis  to accelerate the R&D of revolutionary oral care and dental products. For the credentis investors, the acquisition presents a successful exit, concluding a nearly decade long collaboration.

“I am overjoyed that we managed to establish credentis as an innovative dental and oral care company, that has become a successful investment case. Furthermore, with this acquisition, the value generated will remain and support growth in Switzerland.”, says Dr Erich Platzer, former President of the Board of Directors of credentis, and lead investor for the business angel group, StartAngelsNetwork.

“This is a dream coming true – after 10 years of scientific research and development of our unique CUROLOX^® TECHNOLOGY and the CURODONT™ products, we will take the next step – establishing the credentis and vVardis products in the dental and OTC markets.”, says Dr Dominik Lysek, CEO of credentis.

“For us, the combination of credentis’ scientific expertise and innovation, and our unique vVardis brand based on our expertise in Dentistry and Oral Care makes the perfect team to revolutionize the oral care and dental market with the best products possible.”, say the Dres Haleh and Golnar Abivardi, CEOs of vVardis.

credentis was founded in 2010 to develop and commercialise self-assembling peptide (SAP) technologies patented by the University of Leeds for dental and oral care applications. The IKC supported a collaborative programme to research and develop novel second-generation peptides with improved function and efficacy to regenerate early dental decay, described as ‘filling without drilling’ which completed in 2016. Collaborative work continued with a new industrial partnership proof of concept project to develop and evaluate the incorporation of antimicrobials for treatment of periodontal disease. credentis continues to develop the family of products based on the Leeds technology, for example, recent clinical trials of Curodont Protect and Curodont Repair show superiority to fluoride varnish in caries prevention and treatment.

Follow credentis on LinkedIn Facebook and Instagram